Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
18h
Vaxcyte’s Strong Market Position and Financial Health Justify Buy Rating with $153 Target
Leerink Partners analyst David Risinger reiterated a Buy rating on Vaxcyte (PCVX – Research Report) on November 5 and set a price target ...
9h
Strong Q3 Performance and Future Growth Prospects Justify Buy Rating on Sarepta Therapeutics
William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today. Sami Corwin’s rating is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
3 charged in Payne's death
Biden addresses nation
Fed cuts interest rates
Trump picks chief of staff
Germany arrests US citizen
Wins in Pennsylvania
Newsom calls special session
Navy fires ethics leader
43 monkeys escape SC lab
Nearly 1 in 6 adults diabetic
Arctic oil refuge plan
Jackson mayor indicted
Israel signs F-15 deal
Giuliani appears in court
9/11 plea deals revived
NYC hotel fraud ruling
Ellison begins 2-yr sentence
Snow back on Mount Fuji
Facebook shareholder suit
Weekly jobless claims rise
Fired by Philadelphia Union
Flips PA Senate seat
Wholesale inventories fall
Nissan to cut 9,000 jobs
Volcano erupts in Indonesia
Pledges 'orderly' transition
Time to get flu, COVID shots
Mortgage rates rise again
Expands bird flu testing
New Pompeii DNA evidence
Feedback